(Q36555966)

14 August 2017

1 reference

title

Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis (English)

1 reference

14 August 2017

1 reference

Cohen RD

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Alimentary Pharmacology & Therapeutics

14 August 2017

published in

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

465-474

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

14 August 2017

1 reference

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Molecular mimicry may contribute to pathogenesis of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Patient adherence and medical treatment outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Influence of inflammatory bowel disease on different dimensions of quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03010.X

10.1111/J.1365-2036.2006.03010.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference